RxDoctor Payments Data

Michael Bodin, MD

Family Medicine · Gonzales, LANPI 1376743427

Payments from drug & device makers

$7,754in general payments, 2019–2025

Across 547 payments — averaging $14.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • GSK$961
  • Boehringer Ingelheim$678
  • Novo Nordisk$459
  • Astellas Pharma US Inc$453
  • Lilly USA, LLC$390
  • plus $3K from 37 others

What the payments were for

  • Food & beverage$7,66699%
  • Education$881%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,754 in reported general payments places this provider in the 85th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$54,000
Medicare patients
122
Services billed
651

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide98$125,189
JardianceEmpagliflozin123$109,279
MounjaroTirzepatide60$93,969
FarxigaDapagliflozin Propanediol51$60,378
Stiolto RespimatTiotropium Br/Olodaterol Hcl68$56,392
TrulicityDulaglutide26$31,426
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$26,115
EliquisApixaban29$24,828
Synjardy XrEmpagliflozin/Metformin Hcl34$22,504
Trijardy XrEmpaglifloz/Linaglip/Metformin24$22,441
LinzessLinaclotide17$19,468
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr23$17,826
SymbicortBudesonide/Formoterol Fumarate40$14,856
JanuviaSitagliptin Phosphate18$14,844
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$13,813

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Stiolto Respimat, Synjardy Xr, Trijardy Xr, Glyxambi$678$224,312273 claims
Lilly USA, LLCMounjaro, Trulicity$390$125,39686 claims
Novo NordiskOzempic$459$125,18998 claims
AstraZenecaFarxiga, Symbicort, Breztri Aerosphere$179$89,048102 claims
GSKTrelegy Ellipta, Anoro Ellipta$961$43,94149 claims
PfizerEliquis, Abrysvo$261$28,27141 claims
AbbVieLinzess$1,370$19,46817 claims
MerckJanuvia$329$14,84418 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$161$12,59318 claims
Astellas Pharma US IncMyrbetriq$453$8,73613 claims
Sumitomo Pharma America, Inc.Gemtesa$18$6,28713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Gonzales

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →